chartmojo

SRPT regression play

Kort
chartmojo Uppdaterad   
NASDAQ:SRPT   Sarepta Therapeutics, Inc.
3
100% pop should regress some
Kommentera:
important Duchens Muscular Dystrophy reversal/approval..small market however
Kommentera:
Frankly after researching this companies drug and Duchenne Muscular Dystrophy i find myself rooting for this company. This stock popped some 95% on an approval of their drug that delays the onset of the debilitating effects of this little known genetic disease in children. While there was and may be more regression opportunities in the price from a technical perspective, especially for a scalper like me, I'm hoping the company's stock actually ultimately goes to the moon and that those dedicated individuals involved in this company prosper because they deserve it.

Frånsägelse av ansvar

Informationen och publikationerna är inte avsedda att vara, och utgör inte heller finansiella, investerings-, handels- eller andra typer av råd eller rekommendationer som tillhandahålls eller stöds av TradingView. Läs mer i Användarvillkoren.